Assessment of the pharmaceutical quality of marketed enteric coated pantoprazole sodium sesquihydrate products

Badwan, 2002, Pantoprazole sodium, Analytical Profiles of Drug Substances and Excipients, 29, 213, 10.1016/S1075-6280(02)29008-4

Bersanetti, 2005, Kinetic studies on clavulanic acid degradation, Biochemical Engineering Journal, 23, 31, 10.1016/j.bej.2004.10.007

Brogmann, 2001, Enteric targeting through enteric coating, 1

Dighe, 1999, A review of the safety of generic drugs, Transplantation Proceedings, 31, 23S, 10.1016/S0041-1345(99)00109-8

FDA, 1997. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Guidance for Industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.

Jungnickel, 2000, Pantoprazole: a new proton pump inhibitor, Clinical Therapeutics, 22, 1268, 10.1016/S0149-2918(00)83025-8

Liu, 2009, A novel concept in enteric coating: a double-coating system providing rapid drug release in the proximal small intestine, Journal of Controlled Release, 133, 119, 10.1016/j.jconrel.2008.09.083

Meyer, 1999, History and regulatory issues of generic drugs, Transplantation Proceedings, 31, 10S, 10.1016/S0041-1345(99)00105-0

Office of Generic Drugs. Center for drug evaluation, food and drug administration (online). <http://www.fda.gov/cder/ogd/index.htm> (accessed 07.09).

Poole, 2001, Pantoprazole, American Journal of Health-System Pharmacy, 58, 999, 10.1093/ajhp/58.11.999

Skinner, 1993, The pH-stability and acid degradation of the macrolide antibiotic, josamycin, European Journal of Pharmaceutical Sciences, 1, 61, 10.1016/0928-0987(93)90019-7

Todd, 1988, Diclofenac sodium, a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, Drugs, 35, 244, 10.2165/00003495-198835030-00004

United States Pharmacopeia and National Formulary, 27th ed., The United States Pharmacopeial Convention Inc., 2004.